U.S. Markets open in 3 hrs 39 mins

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2500-0.0600 (-4.58%)
At close: 03:59PM EST

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660
United States
360 980 8524

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott A. Kelly FAAPMR, M.D.Chairman, Chief Medical Officer & Head of Bus. Devel.1.05MN/A1970
Dr. Nader Z. Pourhassan Ph.D.CEO, Pres & Director2.06MN/A1963
Dr. Nitya G. Ray Ph.D.COO & CTO797.5kN/A1953
Mr. Antonio Migliarese CPACFO & TreasurerN/AN/A1983
Mr. Michael D. Mulholland CPA, CPASr. VP of Fin.N/AN/A1952
Mr. George BitarHead of Quality & Exec. DirectorN/AN/AN/A
Dr. Christopher P. Recknor M.D.Sr. Exec. VP of Clinical OperationsN/AN/A1965
Dr. Kush DhodySr. VP of Clinical OperationsN/AN/AN/A
Dr. Denis R. BurgerScientific ConsultantN/AN/A1944
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Corporate Governance

CytoDyn Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.